Knee Brace Design

The USPTO granted design patent USD1121163S1 for a knee brace to Guangdong Transcontinental Technology Co., Ltd. The patent covers the ornamental design of the knee brace with one claim. Filing date was December 5, 2024, and the grant date is March 31, 2026.

Penile sleeve implant patent granted to Loria Cosmetic Urology

USPTO granted Design Patent USD1121151S1 to Loria Cosmetic Urology LLC for a penile sleeve implant. The patent was issued on March 31, 2026, with Victor Loria listed as the sole inventor and one design claim. CPC classifications indicate the device falls under male reproductive system medical devices (A61F 2/26, A61F 5/41).

Thumb brace design patent

USPTO issued Design Patent USD1121164S1 to Dongguan Feibu Industrial Co., Ltd. for a thumb brace. The patent, with a single claim, was granted March 31, 2026, based on application filed January 14, 2025.

Compliant Biological Scaffold with Biaxial Expansion

USPTO granted patent US12588985B2 to inventor Brent Schultz for a compliant biological scaffold incorporating elongated apertures arranged in geometric patterns that enable biaxial expansion or contraction. The scaffold may be formed in biological material in vivo or ex vivo and has applications in prosthetics and medical implants. The patent contains 25 claims and is classified under CPC codes A61F 2/86, A61F 2/90, and A61F 2/0063.

Peptide-derived KDM5C targeting cancer therapeutics patent grant

USPTO granted Patent US12589160B2 to NUVOBIO CORPORATION covering peptide-derived therapeutics targeting KDM5C for cancer treatment. The patent, filed on March 12, 2020, contains 6 claims and names inventors Kyle Kevin Biggar, Hemanta Adhikary, and Matthew Jacob Hoekstra. This grant establishes exclusive intellectual property rights for the assignee in the United States.

Multivalent HVT vector vaccine for poultry

USPTO granted Patent US12589147B2 to Intervet Inc. for a recombinant herpesvirus of turkeys (rHVT) vector vaccine expressing antigens from IBDV, NDV, and AIV. The patent covers 20 claims and can be used to vaccinate poultry against four diseases: MDV, IBDV, NDV, and AIV simultaneously.

HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas

The USPTO granted Patent US12589142B2 to PMCR GmbH covering pharmaceutical compositions comprising HLA-A tumor antigen peptides (4-8 peptides for MHC class I and 2+ for MHC class II) for treating breast carcinomas. The patent includes 4 claims and covers methods for preparing the composition and determining HLA peptides.

Ruxolitinib formulation for reduction of itch in atopic dermatitis

USPTO granted Patent US12589096B2 to Incyte Corporation on March 31, 2026. The patent covers a topical 0.75% or 1.5% ruxolitinib cream formulation administered two times per day for reducing itch in patients with atopic dermatitis. The patent includes 20 claims and names Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, and Jim Lee as inventors.

Glucocorticoid receptor modulator relacorilant with paclitaxel patent granted

USPTO granted patent US12589094B2 to Corcept Therapeutics Incorporated on March 31, 2026, covering methods of co-administering glucocorticoid receptor modulator relacorilant with paclitaxel by reducing paclitaxel dose to approximately half when used together. The patent addresses drug-drug interaction management, noting that despite in vitro predictions of 5-fold increased paclitaxel exposure, in vivo co-administration showed only 80% increase, enabling a safer combination therapy for treating cancers such as ovarian and pancreatic.

C2-C7 alkyl boronic acids as antimicrobial antiviral therapeutic compounds

USPTO granted patent US12589103B2 to Cornell University covering methods for treating bacteria and viruses using C2-C7 alkyl boronic acids to reduce growth and virulence. The patent, filed October 7, 2020, names inventors Kenneth W. Simpson, Shiying Zhang, and Michael Fischbach and contains 28 claims.

Injectable sustained-release formulations for treatment of joint pain and inflammation

USPTO granted patent US12589102B2 to FORDOZ Pharma Corp. covering injectable drug-loaded microspheres combining steroidal and non-steroidal anti-inflammatory drugs for sustained release. The patent also protects methods of making the microspheres and using them to treat rheumatoid arthritis and osteoarthritis. The patent contains 9 claims and names inventors Sydney Ugwu, James He, and Zengli Fu.

ALPHA-1062 Pharmaceutical Composition for Treating Traumatic Brain Injury

USPTO granted Patent US12589099B2 to Alpha Cognition Inc. for a pharmaceutical composition containing ALPHA-1062 (or salt thereof) for treating confirmed or suspected traumatic brain injury (TBI). The patent includes 27 claims covering transmucosal/intranasal administration methods and a multi-use dispenser configuration. The composition may be self-preserving and anti-microbial.

Regeneron cyclodextrin protein drug conjugates

USPTO granted patent US12589101B2 to Regeneron Pharmaceuticals for cyclodextrin protein drug conjugates used in treating proliferative diseases. The patent contains 41 claims and covers compounds, compositions, and conjugates with cyclodextrin-based linker-payloads. Inventors: Amy Han and William Olson. Filing date: June 10, 2022.

Plasma kallikrein inhibitor patent for ocular disorders

The USPTO granted BioCryst Pharmaceuticals patent US12589093B2 covering plasma kallikrein inhibitor compositions for treating ocular disorders. The patent claims avoralstat-based drug compositions delivered via suprachoroidal space injection. The patent contains 16 claims and names inventors Yarlagadda Babu, Viral Kansara, and Rick McElheny.

Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK

Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK

NCLAT Supplementary Cause List - Chairperson's Court

The National Company Law Appellate Tribunal (NCLAT) published a supplementary cause list for the Chairperson's Court scheduled for April 1, 2026, listing various insolvency proceedings, appeals, and interlocutory applications. The list includes case numbers (e.g., Comp. App. (AT) No. 167 of 2026, I.A. No. 2195 of 2026), party names, and counsel information, with matters being heard via video conferencing.

NCLAT Court III Supplementary Cause List - Daily Hearing Schedule

NCLAT Court III published its supplementary daily cause list for April 1, 2026, scheduling hybrid video conference hearings at 2:00 PM before a three-member bench. The list includes one company appeal (Comp. App. (AT) No. 526 of 2025) concerning Rakesh Dalpatram Panchal vs. Muskan Kisaan Steels Pvt. Ltd., with procedural instructions for virtual court participation.

NCLAT Registrar Court Daily Cause List

NCLAT Principal Bench published the daily cause list for the Registrar Court dated April 1, 2026, scheduled at 11:30 AM in hybrid mode. Three interim applications were listed for consideration under Rule 26(3) of NCLAT Rules, 2016, involving disputes between Yogesh Kumar Thakkar and Narinder Kaur, Canara Bank and Indian Overseas Bank, and Vinay Gupta and Oswal Minerals Limited.

Crystalline Salts of Plasma Kallikrein Inhibitor Patent

USPTO granted patent US12590069B2 to BioCryst Pharmaceuticals, Inc. covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, pharmaceutical preparations, and methods of treatment. The patent (30 claims) names inventors Yahya El-Kattan and Yarlagadda S. Babu, with an August 28, 2025 filing date. This is a routine patent grant establishing intellectual property protection with no new regulatory compliance obligations.

Thyromimetics Patent - Autobahn Therapeutics

USPTO granted patent US12590072B2 to Autobahn Therapeutics, Inc. covering thyromimetic compounds for treating neurodegenerative disorders and fibrotic diseases. The patent (20 claims) names inventors Thomas von Geldern and Bradley Backes, with original filing date June 17, 2021. This is a routine patent grant notice with no compliance obligations.

Crystalline salts of plasma kallikrein inhibitor patent grant

USPTO granted BioCryst Pharmaceuticals, Inc. Patent US12590068B2 covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, and related pharmaceutical preparations. Inventors: Yahya El-Kattan and Yarlagadda S. Babu. The patent contains 30 claims and 3 CPC classifications (C07D 231/14, A61K 9/0029, C07B 2200/13).

Adamantane derivatives as inhibitors of focal adhesion kinase

USPTO granted patent US12590070B2 to Samjin Pharmaceutical Co., Ltd. on March 31, 2026, covering novel adamantane derivatives as inhibitors of focal adhesion kinase (FAK) for pharmaceutical use. The patent includes 17 allowed claims and covers compounds, salts, stereoisomers, and pharmaceutical compositions. The invention is classified under CPC codes including C07D 239/48, C07D 401/12, and A61P 35/00 (antineoplastic agents).

Hydrazone derivative with aryl-substituted terminal amine group and use thereof

USPTO granted Patent No. US12590071B2 to Korea Institute of Science and Technology on March 31, 2026, covering hydrazone derivatives where the terminal amine group is substituted with aryl or heteroaryl groups. The patent includes 14 claims relating to compounds represented by Formulas 3 and 4, and methods of making these compounds. The patent relates to heterocyclic organic chemistry with potential pharmaceutical applications.

Process for preparation of macrocyclic chelant and metal complexes

USPTO granted patent US12590073B2 to Biophore India Pharmaceuticals Pvt. Ltd. for an improved process preparing macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid and its gadolinium/calcium metal complexes with purity exceeding 99.0% by HPLC. The patent names inventors Manik Reddy Pullagurla and Jagadeesh Babu Rangisetty, with 9 claims granted.

Method of fixating carbon dioxide to substituted oxazolidinones using MOF technology

USPTO granted patent US12590074B2 to King Fahd University of Petroleum and Minerals on March 31, 2026. The patent covers a method of fixating carbon dioxide (CO2) to form substituted oxazolidinones using a MIL-68(In)-X metal-organic framework (MOF) catalyst, reacting CO2 with epoxides and aromatic amines. The patent contains 20 claims and application number 18329092.

Extension of Review Period for Cboe DPM Appointments

The SEC issued an order on March 25, 2026, extending its review period for Cboe Exchange's proposed rule change (SR-CBOE-2026-016) regarding Designated Primary Market-Maker appointments across multiple trading sessions. The extension pushes the SEC's decision deadline to May 14, 2026. The original proposed rule change was published February 13, 2026, and no public comments were received.

Extension of OMBPRA Submission for Ombudsman Matter Management System

The SEC's Office of the Ombudsman is seeking an extension of its Paperwork Reduction Act approval for the Ombudsman Matter Management System (OMMS) Submission Form without any changes to the form or its requirements. The OMMS is a voluntary electronic form used by retail investors to contact the SEC regarding complaints, questions, tips, or feedback about the agency or self-regulatory organizations. Approximately 1,500 investor contacts are received annually through this system.

NSCC New Net Margin Account Option for Agent Clearing Members

SEC published NSCC's proposed rule change to offer a new net margin account option for Agent Clearing Members in its SFT Clearing Service. The proposal would allow Agent Clearing Members to elect a net margin treatment for Agent Clearing Member Transactions, potentially reducing margin requirements. Comments are being solicited from interested persons.

Cboe Exchange Auction Response Processing Rule Change

The SEC published a Notice and Order on March 25, 2026, approving Cboe Exchange's proposed rule change (SR-CBOE-2025-074, Amendment No. 1) to amend the maximum processing time for auction responses in non-FLEX options classes. The proposal provides additional support and minor textual changes without substantive modifications to the original filing. The SEC is soliciting public comment on Amendment No. 1 on an accelerated approval timeline.

Cboe C2 Exchange Clock Service

The SEC published notice of Cboe C2 Exchange's proposed rule change to introduce a new optional Clock Service for time synchronization between the Exchange and subscribers. The service would allow TPHs and non-TPHs to synchronize their time recording systems to the Exchange's clock for more precise latency measurements related to orders and messages. Comments are being solicited from interested persons.

Exemptive Order Application for BDC and Closed-End Fund Co-Investment

SEC published notice of an application by Lord Abbett Private Credit Fund and 18 affiliated entities requesting an exemptive order under sections 17(d) and 57(i) of the Investment Company Act of 1940. The application seeks permission for certain business development companies (BDCs) and closed-end management investment companies to co-invest in portfolio companies with each other and affiliated entities. Interested persons have until April 21, 2026 to request a hearing on the application.

Padron, Skin Laundry Holdings diversity case, San Francisco

Padron, Skin Laundry Holdings diversity case, San Francisco

NASA Discrimination Complaint Form Revision

NASA published a Paperwork Reduction Act notice seeking public comment on revisions to NASA Complaint of Discrimination Form 1355 (OMB No. 2700-0163). The form is used by federal employees, former employees, and job applicants to file formal discrimination complaints under 29 CFR Part 1614. Comments are due by May 29, 2026, via Regulations.gov under NASA Docket 2026-0035.

Reporting Purchases from Sources Outside the United States - PRA Extension

NASA, on behalf of the FAR Council, has issued a notice announcing the extension of OMB Control No. 9000-0161 for the information collection requirement on Reporting Purchases from Sources Outside the United States. The collection covers FAR provision 52.225-18 requiring contractors to indicate whether manufactured end products are predominantly manufactured in the US or outside. The extension affects approximately 23,134 respondents with 1,295,504 total annual responses and 12,955 burden hours. Comments on this notice must be submitted by April 29, 2026.

NASA Software Catalog Information Collection Renewal

NASA published a Paperwork Reduction Act notice seeking public comments on renewal of OMB Control Number 2700-0193 for the NASA Software Catalog information collection. The collection covers software request forms from government entities, companies, academic institutions, and individuals seeking Software Usage Agreements. NASA estimates 7,000 annual respondents with a 1-hour burden per response, totaling 7,000 annual burden hours.

Whistleblower Award Program for AML and Sanctions Violations

FinCEN published a Notice of Proposed Rulemaking to establish a whistleblower award program offering 10-30% of collected monetary penalties for tips leading to successful enforcement actions. The program covers fraud-related Bank Secrecy Act violations, OFAC sanctions evasion, and other illicit finance activity under the Anti-Money Laundering Act (2020) and AML Whistleblower Improvement Act (2022).

FinCEN Advisory on Health Care Fraud Targeting Medicare, Medicaid, and Federal Health Programs

FinCEN issued an advisory on health care fraud schemes targeting Medicare, Medicaid, and other federal and state health care benefit programs. The advisory provides financial institutions with an overview of fraud tactics used by fraudsters, organized crime groups, and transnational criminal organizations, along with money laundering typologies and red flag indicators. Financial institutions are strongly encouraged to voluntarily report suspicious activity to FinCEN and immediately notify law enforcement.

Israel Foreign Exchange Reserves 2025 Annual Report

The Bank of Israel published its annual report on the investment of Israel's foreign exchange reserves for 2025. Israel's foreign exchange reserves increased by approximately $14.9 billion to $229.5 billion at year-end 2025. The portfolio achieved a 7.9% return in 2025, compared to 6.7% in 2024, driven by capital gains on equities, interest income, and exchange rate differentials.

CIRA HEALTH SOLUTIONS Trademark Application - Medical Services

The USPTO published trademark application TM87528125 for CIRA HEALTH SOLUTIONS covering medical services in Class 044. The application includes web portal software for managing medical documents, invoices, and scheduling; independent medical examinations; health assessments; medical file reviews; and expert witness services for legal matters in the medical field. This is an Intent to Use application filed on July 14, 2017.

AOX Pte Ltd Penalized for Misusing CCS Logo

The Competition and Consumer Commission of Singapore (CCCS) has taken enforcement action against AOX Pte. Ltd., a water filter company, for misusing CCS's logo in marketing materials and falsely claiming CCS verification of product findings. AOX admitted the offence and provided a binding undertaking to cease using the logo, refrain from unfair trade practices, and issue clarifications at its retail outlets and website.

Virtual Asset Service Provider FAQs

The Bank of Ghana published FAQs explaining the Virtual Asset Service Providers Act, its objectives, and what it means for consumers, businesses, and the financial system. The document addresses common questions about virtual asset regulation in Ghana and provides downloadable PDF guidance.

Six NH High Schools Compete in FinLit 300 Championship

The New Hampshire Banking Department announces the 2026 FinLit 300 State Championship on March 31, 2026 at Grappone Conference Center in Concord. Six New Hampshire high schools will compete in a quiz bowl style event testing student knowledge across six financial literacy categories aligned with national personal finance standards. The competition is hosted by the NH Jump$tart Coalition and open to students and schools across the state.

FTC Consumer Alert on Unclaimed Property Scam Emails

The Federal Trade Commission issued a consumer alert warning the public about scammers sending fraudulent emails and texts claiming recipients are eligible for unclaimed property. The scam involves phishing attempts where fraudsters impersonate government agencies, demand upfront processing fees, and pressure victims to act immediately. The FTC advises consumers not to click on unexpected links and to verify claims only through official state .gov websites.

Climate Change (Just Transition Commission) Regulations (Northern Ireland) 2026

The Department of Agriculture, Environment and Rural Affairs (Northern Ireland) has published draft Climate Change (Just Transition Commission) Regulations 2026 under section 37 of the Climate Change Act (Northern Ireland) 2022. These draft Regulations establish the Just Transition Commission as a new advisory body with oversight functions to review and report on the implementation of just transition elements in sectoral plans, climate action plans, and related schemes. The Commission may request information from public bodies and must prepare annual reports for the Northern Ireland Assembly.

City of Duluth Settlement for 2024 Fishkill Incident

MPCA announced a settlement with the City of Duluth for a fishkill incident in Tischer Creek. The city will pay a $12,000 fine and $190,000 in natural resource damage assessment (NRDA) compensation. The August 2024 incident killed approximately 2,300 fish, including nearly 1,600 brook trout, after treated drinking water containing chlorine and ammonia was released into the creek.

Class exemption simplifies green, social, sustainability bond issuance

The FMA granted a class exemption enabling issuers to offer green, social, sustainability and sustainability-linked (GSSS) bonds without the usual product disclosure statement requirements. The exemption aligns with the Financial Markets Conduct Act 'same class' exclusion, allowing issuers with existing quoted bonds to issue GSSS bonds with modified interest rates, redemption dates, and GSSS features more quickly and cost-effectively. Issuers must still make GSSS-related information available to investors.

Relief for foreign AFS licensees and ADIs remade by ASIC

ASIC remade ASIC Corporations (Foreign Licensees and ADIs) Instrument 2026/121, which exempts foreign AFS licensees from certain record-keeping and financial statement obligations under the Corporations Act 2001, and exempts foreign ADIs from AFS licence requirements when dealing in derivatives and FX contracts on their own behalf. ASIC also extended relief for lease asset calculations for AFS licensees to 1 May 2031.

ASIC Remakes Technical Relief and Credit Disclosure Instruments

ASIC has remade two legislative instruments providing technical relief to Australian financial services licensees and modifying reverse-mortgage disclosure requirements for credit licensees. The instruments will expire on 1 April 2031. ASIC consulted on the remakes in December 2025 and received no submissions.

INVEST-CON Finanzconsulting granted investment services licence

The Austrian Financial Market Authority (FMA) granted INVEST-CON Finanzconsulting GmbH a licence as an investment services provider pursuant to Article 4 of the Securities Supervision Act 2018 (WAG 2018). The company previously held a licence as an investment firm under Article 3 WAG 2018, which was progressively relinquished. The licence became effective on 16 March 2026 following the fulfillment of a condition precedent.

Solvency II Microsite and Insurance Supervision Guidance

The Austrian Financial Market Authority (FMA) launched a new microsite dedicated to Solvency II, the EU-wide insurance supervision framework. The microsite organizes content across four thematic areas: significant elements and aims of Solvency II, the three-pillar supervisory approach, national and European developments, and recovery and resolution of insurance undertakings. This is an informational resource designed to improve transparency and accountability in Austrian insurance supervision.